A detailed history of Mutual Of America Capital Management LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Mutual Of America Capital Management LLC holds 202,654 shares of SUPN stock, worth $7.42 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
202,654
Previous 278,436 27.22%
Holding current value
$7.42 Million
Previous $7.45 Million 15.17%
% of portfolio
0.07%
Previous 0.08%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$25.77 - $35.16 $1.95 Million - $2.66 Million
-75,782 Reduced 27.22%
202,654 $6.32 Million
Q2 2024

Aug 09, 2024

SELL
$25.99 - $33.85 $1.1 Million - $1.44 Million
-42,484 Reduced 13.24%
278,436 $7.45 Million
Q1 2024

May 02, 2024

SELL
$27.11 - $35.17 $455,095 - $590,398
-16,787 Reduced 4.97%
320,920 $10.9 Million
Q4 2023

Jan 26, 2024

SELL
$22.72 - $29.68 $191,029 - $249,549
-8,408 Reduced 2.43%
337,707 $9.77 Million
Q3 2023

Nov 09, 2023

SELL
$27.57 - $32.91 $48,798 - $58,250
-1,770 Reduced 0.51%
346,115 $9.54 Million
Q2 2023

Aug 11, 2023

SELL
$29.91 - $38.73 $123,348 - $159,722
-4,124 Reduced 1.17%
347,885 $10.5 Million
Q1 2023

May 04, 2023

SELL
$34.93 - $42.03 $443,261 - $533,360
-12,690 Reduced 3.48%
352,009 $12.8 Million
Q4 2022

Feb 10, 2023

SELL
$31.09 - $37.88 $317,180 - $386,451
-10,202 Reduced 2.72%
364,699 $13 Million
Q3 2022

Nov 08, 2022

SELL
$28.79 - $35.41 $225,799 - $277,720
-7,843 Reduced 2.05%
374,901 $12.7 Million
Q2 2022

Aug 10, 2022

BUY
$25.33 - $34.25 $416,729 - $563,481
16,452 Added 4.49%
382,744 $11.1 Million
Q1 2022

May 02, 2022

SELL
$28.51 - $32.9 $177,246 - $204,539
-6,217 Reduced 1.67%
366,292 $11.8 Million
Q4 2021

Feb 03, 2022

SELL
$26.37 - $34.22 $74,442 - $96,603
-2,823 Reduced 0.75%
372,509 $10.9 Million
Q3 2021

Nov 10, 2021

BUY
$23.54 - $31.39 $1.39 Million - $1.85 Million
59,031 Added 18.66%
375,332 $10 Million
Q2 2021

Aug 06, 2021

SELL
$26.72 - $33.19 $921,385 - $1.14 Million
-34,483 Reduced 9.83%
316,301 $9.74 Million
Q1 2021

May 13, 2021

SELL
$24.15 - $31.45 $131,400 - $171,119
-5,441 Reduced 1.53%
350,784 $9.18 Million
Q4 2020

Feb 12, 2021

SELL
$17.7 - $25.81 $39,665 - $57,840
-2,241 Reduced 0.63%
356,225 $8.96 Million
Q3 2020

Nov 13, 2020

SELL
$20.2 - $25.05 $481,366 - $596,941
-23,830 Reduced 6.23%
358,466 $7.47 Million
Q2 2020

Aug 06, 2020

BUY
$17.09 - $24.89 $758,129 - $1.1 Million
44,361 Added 13.13%
382,296 $9.08 Million
Q1 2020

May 11, 2020

SELL
$14.45 - $24.69 $853,908 - $1.46 Million
-59,094 Reduced 14.88%
337,935 $6.08 Million
Q4 2019

Feb 11, 2020

BUY
$19.93 - $29.13 $98,434 - $143,873
4,939 Added 1.26%
397,029 $9.42 Million
Q3 2019

Nov 14, 2019

BUY
$25.47 - $33.37 $205,619 - $269,396
8,073 Added 2.1%
392,090 $10.8 Million
Q2 2019

Aug 12, 2019

SELL
$29.96 - $38.87 $1.1 Million - $1.43 Million
-36,782 Reduced 8.74%
384,017 $12.7 Million
Q1 2019

May 13, 2019

BUY
$32.77 - $41.99 $157,492 - $201,803
4,806 Added 1.16%
420,799 $14.7 Million
Q4 2018

Feb 12, 2019

BUY
$30.84 - $49.51 $1.69 Million - $2.71 Million
54,661 Added 15.13%
415,993 $13.8 Million
Q3 2018

Nov 13, 2018

BUY
$42.7 - $56.55 $2.21 Million - $2.93 Million
51,776 Added 16.73%
361,332 $18.2 Million
Q2 2018

Aug 09, 2018

SELL
$44.1 - $59.85 $3.52 Million - $4.77 Million
-79,715 Reduced 20.48%
309,556 $18.5 Million
Q1 2018

May 11, 2018

SELL
$37.15 - $46.9 $39,824 - $50,276
-1,072 Reduced 0.27%
389,271 $17.8 Million
Q4 2017

Jan 31, 2018

SELL
$36.4 - $42.6 $444,880 - $520,657
-12,222 Reduced 3.04%
390,343 $15.6 Million
Q3 2017

Oct 18, 2017

BUY
$36.75 - $49.65 $14.8 Million - $20 Million
402,565
402,565 $16.1 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.96B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Mutual Of America Capital Management LLC Portfolio

Follow Mutual Of America Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mutual Of America Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mutual Of America Capital Management LLC with notifications on news.